Table 3.
Patient-reported improvement, headache frequency, and migraine pain intensity
| Parameter | P value | |
|---|---|---|
| Improvement, n (%)a | (n = 129) | |
| Yes | 108 (84) | |
| No | 21 (16) | |
| Headache frequency (overall) | (n = 54) | |
| Pre-index, mean (SD) | 22.24 (9.29) | |
| Post-index, mean (SD) | 8.24 (7.42) | |
| Difference in days, meanb | 14.00 | < 0.001 |
| Difference %, mean | 63% | |
| MPI (overall) | (n = 74) | |
| Pre-index, mean (SD) | 5.47 (3.19) | |
| Post-index, mean (SD) | 4.51 (3.34) | |
| Difference in days, meanb | 0.96 | 0.014 |
| Difference %, mean | 18% |
SD standard deviation, MPI migraine pain intensity
aNot reported, n = 43
bNonparametric Wilcoxon signed-rank tests, with a level of significance set at P < 0.05, were used to compare means of patient-reported headache frequency and MPI before and after fremanezumab initiation